Table 4 Univariate–multivariate overall survival analysis in patients receiving gemcitabine plus Nab Paclitaxel.
From: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Variable | Overall survival | |||||
|---|---|---|---|---|---|---|
Univariate | Multivariate | |||||
HR | %95 Cl | P value | HR | %95 Cl | P value | |
Age | 0.99 | 0.98-1.01 | 0.88 | |||
Gender (Male*/Female) | 0.93 | 0.69-1.25 | 0.65 | |||
CEA level | 1.02 | 1.01-1.03 | <0.01 | 1.02 | 1.01-1.03 | <0.01 |
CA 19-9 level | 1.00 | 1.00-1.00 | 0.14 | |||
ECOG (0-1*/2) | 1.60 | 1.18-2.17 | 0.02 | 1.73 | 1.04-2.22 | 0.01 |
Metastatic at diagnosis (no*/yes) | 1.45 | 1.02-2.05 | 0.03 | 1.52 | 1.04-2.41 | 0.02 |
